Companies → Johnson & Johnson

Save to list

Remove

Johnson & Johnson

United States, New Jersey, New Brunswick

Report a bug?

Claim ownership and edit

Description

Johnson & Johnson (J&J) is engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The company is organized into two business segments: Innovative Medicine and MedTech. Its Pharmaceuticals segment is focused on manufacturing medicines for immunology, infectious diseases, neuroscience, cardiovascular, metabolism, pulmonary hypertension, and oncology ailments. Its MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular), and Vision fields. The company operates worldwide but makes about 55% of its revenue in the US.

Industries

Pharmaceutical and Medicine Manufacturing; Converted Paper Product Manufacturing; Medical Equipment and Supplies Manufacturing; Health and Personal Care Retailers; Professional and Commercial Equipment and Supplies Merchant Wholesalers

SIC

Pharmaceutical Preparations; Converted Paper and Paperboard Products, Except Containers and Boxes; Surgical and Medical Instruments; Drug Stores and Proprietary Stores; Professional and Commercial Equipment and Supplies

Address:

1 Johnson AND Johnson Plz New Brunswick

08933-0002 United States

Website:

www.jnj.com

Revenue

Recent news:

Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone

Protagonist Therapeutics (NASDAQ:PTGX) executives said March 18 that the U.S. Food and Drug Administration has approved ICOTYDE for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms and are candidates for s

Source: MarketBeat Mar 21, 2026

Jim Cramer on Johnson & Johnson: “It’s a Textbook Slowdown Stock”

Johnson & Johnson (NYSE:JNJ) is one of the stocks mentioned during the show, as we cover everything Jim Cramer said about the oversold market. Cramer was quite bullish on the company’s stock, as he stated: Yesterday, we got some terrific news from Johnson & Johnson, but because the tape was so ugly, the stock did

Source: Insider Monkey Mar 21, 2026

Monte Rosa J J Supply Deal Refocuses MRT 2359 Prostate Cancer Story

Monte Rosa Therapeutics (NasdaqGS:GLUE) announced a new supply agreement with Johnson & Johnson to evaluate MRT-2359 with ERLEADA in metastatic castration resistant prostate cancer. The company is initiating a Phase 2 trial of the MRT-2359 plus ERLEADA combination in this setting. Additional positive clinical data for MRT-2359 in advanced prostate cancer were presented at ASCO GU 2026. Monte Rosa Therapeutics enters this news cycle with its shares at $15.63 and a 1 year return of 169.5%...

Source: Simply Wall St. Mar 21, 2026

Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why

PTGX stock jumps as JNJ wins FDA nod for Icotyde in plaque psoriasis, unlocking milestone payments and royalty potential for Protagonist.

Source: Zacks Mar 20, 2026

Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?

Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Source: Zacks Mar 20, 2026

After notable victories, anti-DEI shareholders turn sights on Trump's SEC

The National Legal and Policy Center has successfully urged companies like Goldman Sachs and American Express to remove DEI from their board selection process, but now it argues that SEC actions are restricting shareholder rights too much.

Source: Financial Planning Mar 20, 2026

NYSE - Delayed Quote - USD

JNJ

235.37 -2.23 (-0.94%)

At close March 20 20:00 UTC

235.37 0.00 (0.00%)

After hours: March 20 23:45 UTC

Candle

Line

Financial Statistics

Valuation Measures

Current

Quarterly

As of 03/21/2026

Market Cap: 566.92 B

Enterprise Value: 594.75 B

Trailing P/E: 21.34

Forward P/E: 20.41

PEG Ratio (5yr expected): 1.64

Price/Sales (ttm): 6.07

Price/Book (mrq): 6.95

Enterprise Value/Revenue: 6.31

Enterprise Value/EBITDA: 14.49

Financial Highlights

Profitability and Income Statement

Profit Margin: 28.46%

Return on Assets (ttm): 8.68%

Return on Equity (ttm): 35.03%

Revenue (ttm): 94.19 B

Net Income Avi to Common (ttm): 26.80 B

Diluted EPS (ttm): 11.04

Balance Sheet and Cash Flow

Total Cash (mrq): 20.10 B

Total Debt/Equity (mrq): 60.50%

Levered Free Cash Flow (ttm): 16.63 B

Company is likely to buy

Company is likely to sell

Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.